Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development

Trends in Pharmacological Sciences

Volumn 30, Issue 12, 2009, Pages 638-646

  Smith, Jessica L ^a   Bu, Wei ^a,b   Burdick, Ryan C ^a   Pathak, Vinay K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 NITROPHENYLTHIO) N PHENYLBENZAMIDE; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BENZAMIDE DERIVATIVE; CYTIDINE DEAMINASE; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; NEVIRAPINE; PROTEASOME; RN 18; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIF PROTEIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CELLULAR IMMUNITY; CYTOTOXICITY; DRUG TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; REVIEW; VIRION; VIRUS INFECTIVITY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CYTOSINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 70449629709     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.09.006     Document Type: Review

References (125)

1. Barouch D.H. Challenges in the development of an HIV-1 vaccine. Nature 455 (2008) 613-619
2. Robb M.L. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372 (2008) 1857-1858
3. Fischl M.A., et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317 (1987) 185-191
4. Arrive E., et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int. J. Epidemiol. 36 (2007) 1009-1021
5. Sax P.E., and Gathe Jr. J.C. Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS 19 (2005) 563-576
6. + lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. Antiviral Res. 29 (1996) 91-93
7. Hoen B., et al. Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. J. Infect. Dis. 180 (1999) 1342-1346
8. Egbertson M.S., et al. A potent and orally active HIV-1 integrase inhibitor. Bioorg. Med. Chem. Lett. 17 (2007) 1392-1398
9. MacArthur R.D., and Novak R.M. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents. Clin. Infect. Dis. 47 (2008) 236-241
10. Moore J.P., and Kuritzkes D.R. A piece de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr. Opin. HIV AIDS 4 (2009) 118-124
11. Hicks C., and Gulick R.M. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 48 (2009) 931-939
12. Liddament M.T., et al. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14 (2004) 1385-1391
13. Wiegand H.L., et al. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23 (2004) 2451-2458
14. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418 (2002) 646-650
15. Zheng Y.H., et al. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J. Virol. 78 (2004) 6073-6076
16. Stremlau M., et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427 (2004) 848-853
17. Sayah D.M., et al. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430 (2004) 569-573
18. Neil S.J., et al. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451 (2008) 425-430
19. Van Damme N., et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3 (2008) 245-252
20. Strebel K., et al. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328 (1987) 728-730
21. Fisher A.G., et al. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237 (1987) 888-893
22. + T lymphocytes. J. Virol. 66 (1992) 6489-6495
23. von Schwedler U., et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67 (1993) 4945-4955
24. Conticello S.G., et al. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22 (2005) 367-377
25. Jarmuz A., et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79 (2002) 285-296
26. Huthoff H., and Malim M.H. Cytidine deamination and resistance to retroviral infection: towards a structural understanding of the APOBEC proteins. Virology 334 (2005) 147-153
27. Dang Y., et al. Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80 (2006) 10522-10533
28. Gooch B.D., and Cullen B.R. Functional domain organization of human APOBEC3G. Virology 379 (2008) 118-124
29. Navarro F., et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 333 (2005) 374-386
30. Iwatani Y., et al. Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80 (2006) 5992-6002
31. Friew Y.N., et al. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 6 (2009) 56
32. Hache G., et al. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280 (2005) 10920-10924
33. Li J., et al. Functional domains of APOBEC3G required for antiviral activity. J. Cell. Biochem. 92 (2004) 560-572
34. Langlois M.A., et al. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities. Nucleic Acids Res. 33 (2005) 1913-1923
35. Peng G., et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110 (2007) 393-400
36. Chen K., et al. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 80 (2006) 7645-7657
37. Koning F.A., et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J. Virol. 83 (2009) 9474-9485
38. Stopak K.S., et al. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282 (2007) 3539-3546
39. Wang F.X., et al. APOBEC3G upregulation by α interferon restricts human immunodeficiency virus type 1 infection in human peripheral plasmacytoid dendritic cells. J. Gen. Virol. 89 (2008) 722-730
40. + T cells. Nature 435 (2005) 108-114
41. Chiu Y.L., et al. High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 15588-15593
42. Mikl M.C., et al. Mice deficient in APOBEC2 and APOBEC3. Mol. Cell. Biol. 25 (2005) 7270-7277
43. Mariani R., et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114 (2003) 21-31
44. Marin M., et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9 (2003) 1398-1403
45. Sheehy A.M., et al. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9 (2003) 1404-1407
46. Stopak K., et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12 (2003) 591-601
47. Svarovskaia E.S., et al. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279 (2004) 35822-35828
48. Zhang H., et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424 (2003) 94-98
49. Mangeat B., et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424 (2003) 99-103
50. Harris R.S., et al. DNA deamination mediates innate immunity to retroviral infection. Cell 113 (2003) 803-809
51. Lecossier D., et al. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300 (2003) 1112
52. Suspene R., et al. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32 (2004) 2421-2429
53. Yu Q., et al. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11 (2004) 435-442
54. Shindo K., et al. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278 (2003) 44412-44416
55. Yang Y., et al. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365 (2007) 92-100
56. Guo F., et al. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80 (2006) 11710-11722
57. Guo F., et al. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. J. Virol. 81 (2007) 11322-11331
58. Iwatani Y., et al. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35 (2007) 7096-7108
59. Bishop K.N., et al. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4 (2008) e1000231
60. Anderson J.L., and Hope T.J. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 375 (2008) 1-12
61. Li X.Y., et al. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282 (2007) 32065-32074
62. Holmes R.K., et al. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282 (2007) 2587-2595
63. Newman E.N., et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15 (2005) 166-170
64. Mbisa J.L., et al. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81 (2007) 7099-7110
65. Luo K., et al. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81 (2007) 7238-7248
66. Miyagi E., et al. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 81 (2007) 13346-13353
67. Schumacher A.J., et al. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 82 (2008) 2652-2660
68. Xu H., et al. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360 (2007) 247-256
69. Yang B., et al. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282 (2007) 11667-11675
70. Kaiser S.M., and Emerman M. Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80 (2006) 875-882
71. Langlois M.A., and Neuberger M.S. Human APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1. J. Virol. 82 (2008) 4660-4664
72. + T-cells. PLoS Pathog. 5 (2009) e1000342
73. + T cells remain refractory to HIV1 infection. PLoS ONE 4 (2009) e6571
74. Vetter M.L., and D'Aquila R.T. Cytoplasmic APOBEC3G restricts incoming Vif-positive HIV-1 and increases 2-LTR circle formation in activated T helper subtype cells. J. Virol. 83 (2009) 8646-8654
75. Conticello S.G., et al. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13 (2003) 2009-2013
76. Mehle A., et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279 (2004) 7792-7798
77. Yu X., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302 (2003) 1056-1060
78. Liu B., et al. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. J. Virol. 79 (2005) 9579-9587
79. Mehle A., et al. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18 (2004) 2861-2866
80. Yu Y., et al. Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18 (2004) 2867-2872
81. Luo K., et al. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11444-11449
82. Mehle A., et al. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281 (2006) 17259-17265
83. Chen K.M., et al. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452 (2008) 116-119
84. Holden L.G., et al. Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456 (2008) 121-124
85. Furukawa A., et al. Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO J. 28 (2009) 440-451
86. Harjes E., et al. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 389 (2009) 819-832
87. Stanley B.J., et al. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82 (2008) 8656-8663
88. Auclair J.R., et al. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins 69 (2007) 270-284
89. Reingewertz T.H., et al. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Eng. Des. Sel. 22 (2009) 281-287
90. Kao S., et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77 (2003) 11398-11407
91. Simon V., et al. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 1 (2005) e6
92. Tian C., et al. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80 (2006) 3112-3115
93. Russell R.A., and Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81 (2007) 8201-8210
94. Schrofelbauer B., et al. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80 (2006) 5984-5991
95. Xu H., et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5652-5657
96. Bogerd H.P., et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3770-3774
97. Mangeat B., et al. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279 (2004) 14481-14483
98. Schrofelbauer B., et al. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3927-3932
99. He Z., et al. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381 (2008) 1000-1011
100. Yamashita T., et al. Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes Infect. 10 (2008) 1142-1149
101. Chen, G. et al. (2009) A patch of positively charged amino acids surrounding the HIV-1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. (in press) DOI:10.1128/JVI.00653-09
102. Dang, Y. et al. (2009) Identification of a novel WxSLVK motif in the N-terminus of HIV and SIV Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. (in press) DOI:10.1128/JVI.00651-09
103. Pery E., et al. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83 (2009) 2374-2381
104. Yang B., et al. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J. Biol. Chem. 278 (2003) 6596-6602
105. Donahue J.P., et al. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 377 (2008) 49-53
106. Zhang L., et al. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370 (2008) 113-121
107. Zhang W., et al. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS ONE 3 (2008) e3963
108. Huthoff H., and Malim M.H. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and virion encapsidation. J. Virol. 81 (2007) 3807-3815
109. Russell R.A., et al. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. J. Virol. 83 (2009) 1992-2003
110. Hache G., et al. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 18 (2008) 819-824
111. Gandhi S.K., et al. Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. J. Virol. 82 (2008) 3125-3130
112. Land A.M., et al. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 82 (2008) 8172-8182
113. Piantadosi A., et al. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. J. Virol. 83 (2009) 7805-7814
114. + T cells in vivo. J. Virol. 79 (2005) 1975-1980
115. Mulder L.C., et al. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 5501-5506
116. Jern P., et al. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 5 (2009) e1000367
117. Russell R.A., et al. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 6 (2009) 16
118. Miller J.H., et al. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 4 (2007) 81
119. Xiao Z., et al. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21 (2007) 217-222
120. Adessi C., and Soto C. Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. 9 (2002) 963-978
121. Martin S.J., et al. Programmed cell death (apoptosis) in lymphoid and myeloid cell lines during zinc deficiency. Clin. Exp. Immunol. 83 (1991) 338-343
122. Treves S., et al. Apoptosis is dependent on intracellular zinc and independent of intracellular calcium in lymphocytes. Exp. Cell Res. 211 (1994) 339-343
123. Cao J., et al. High-throughput human immunodeficiency virus type 1 (HIV-1) full replication assay that includes HIV-1 Vif as an antiviral target. Antimicrob. Agents Chemother. 49 (2005) 3833-3841
124. Mehle A., et al. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. J. Virol. 81 (2007) 13235-13241
125. Nathans R., et al. Small-molecule inhibition of HIV-1 Vif. Nat. Biotechnol. 26 (2008) 1187-1192